ArticleGenetic epidemiology2026
Deep Unsupervised Domain Adaptation for Translating Cancer Dependency Maps From Cell Lines to Breast Cancer Tumor Genomics.
Article in Genetic epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Cancer dependency maps (DepMap) identify genetic dependencies in cancer cells using large-scale loss-of-function screens, providing a foundation for cancer-specific treatment strategies. However, discrepancies exist between cancer cell line models (CCLs) and patient-derived tumor models, particularly in translating findings to clinical settings. To bridge this gap, computational approaches such as artificial intelligence-based domain adaptation can assist in aligning laboratory and patient-derived molecular data, thereby improving the translation of preclinical findings into personalized treatment strategies. We developed a deep unsupervised domain adaptation (UDA) algorithm to align features between source and target domains. It was trained on labeled CCLs data from the source domain and unseen, unlabeled CCL data from the target domain. The trained model was applied to predict the dependency map of breast cancer (BC) patients in The Cancer Genome Atlas (TCGA). To validate its performance, we used the predicted BC dependency map to classify ER + /HER2 + BC subtype statuses and identify synthetic lethality (SL) gene pairs for drug discovery. Our model demonstrated high accuracy in predicting cancer dependency maps for patient-derived tumors. The generated maps showed excellent performance in predicting ER + /HER2+ subtype statuses, with an area under the curve of the receiver operating characteristic (AUC-ROC) of 0.99. Notably, our analysis also identified two potential synthetic lethality gene pairs: PBRM1-NF2 and PBRM1-CTNND2, which can be potentially used for developing precision therapies for ER + /HER2+ breast cancer. Domain adaptation is a promising approach for transferring biological knowledge between different cancer models and improving patient-specific treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.